Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Capravirine
DRUG: Nelfinavir mesylate

Sponsor

Agouron Pharmaceuticals